BOSTON , April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today the appointment
Appointment augments board capabilities with a seasoned business development executive as Cue Biopharma executes its next stage of corporate development CAMBRIDGE, Mass. , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a
BOSTON , Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today that it has
Matteo Levisetti, M.D., promoted to Chief Medical Officer, effective January 17, 2023 Acting CMO Kenneth Pienta , M.D., to transition to a clinical advisory role BOSTON , Jan. 23, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a
- Ongoing Phase 1 dose escalation and expansion study with CUE-101 as a monotherapy in post first-line recurrent/metastatic HNSCC patients to be amended to include combination of CUE-101 with standard of care KEYTRUDA as first-line therapy - Preliminary data from early patient cohorts in the
CAMBRIDGE, Mass. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today the publication of research
Collaboration to Study Immuno-STAT Biologics on T Cell Immunological Synapse Formation Using the IL-2-Based CUE-100 Series CAMBRIDGE, Mass. , May 14, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable
CAMBRIDGE, Mass. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today the
BOSTON , Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today a collaboration
Company Integrates Operational Oversight with Dr. Suri’s Expertise in Immunology CAMBRIDGE, Mass. , Oct. 07, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE) a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate